Yeon Hee Park, MD | Authors


PFS Data Support Approval of Fam-Trastuzumab Deruxtecan-nxki for HER2+ Breast Cancer

June 01, 2020

Yeon Hee Park, MD, discusses the data supporting the FDA’s accelerated approval of fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.